Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Contrave naltrexone hydrochloride and bupropion hydrochloride Chronic weight management in adults Do not reimburse Complete
Onivyde Nanoliposomal Irinotecan Cancelled
Tysabri natalizumab Multiple Sclerosis, relapsing-remitting Withdrawn
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting List with clinical criteria and/or conditions Complete
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting Do not list Complete
Bystolic Nebivolol Hypertension Do not list at the submitted price Complete
Atriance Nelarabine Cancelled
Atriance nelarabine T-cell acute lymphoblastic leukemia Reimburse with clinical criteria and/or conditions Complete
Nerlynx Neratinib ERBB2-positive breast cancer Do not reimburse Complete
Akynzeo netupitant / palonosetron Nausea and vomiting (chemotherapy induced) prevention Reimburse with clinical criteria and/or conditions Complete